Phase III PEMPHIX study shows Roche?s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate mofetil
- Study reinforces efficacy and safety of MabThera/Rituxan for treatment of PV, a rare autoimmune condition characterised by blistering of the skin and mucous membranes
- Full data of the 52-week treatment period presented at 28th Congress of the European Academy of Dermatology and Venereology (EADV) in Madrid